In this study we investigated the effect of plant polyphenol PTK inhibitor genistein on subcutaneous human transplant ovarian cancer tumor of nude mice. All 30 cases of nude mice are used to establish subcutaneous xenograft models of human ovarian cancer, and divided into 4 groups: Control group (containing 0.04% DMSO of saline); Genistein group (containing 0.2 mg / kg and 0.4 mg/kg two concentrations, subcutaneous injection); Cisplatin group (4 mg/kg, i.v.); Genistein and Cisplatin combination group. The transplanted tumor growth and weight changes of nude mice in different groups on 7, 14, 21 and 28 days were observed and histopathological examined. The results showed that the growth of SKOV3 xenograft tumor was significantly inhibited in 0.4 mg/kg Genistein group. Compared with control group, the tumor weights were decreased, the tumor volumes were reduced, and there was a significant increase in the area of necrosis, but no significant effects were showed on the weights of nude mice. 0.4 mg/kg Genistein (s.c.) in combination with 4 mg/kg Cisplatin (i.v.) enhanced the inhibitory effect. The results provide evidence for the potential usefulness of Genistein in the prevention and treatment of human ovarian carcinoma.
Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
